Novel luminescent silica nanoparticles (LSN): P53 gene delivery system in breast cancer in vitro and in vivo

Journal of Pharmacy and Pharmacology

Volumn 68, Issue 3, 2016, Pages 305-315

  Rejeeth, Chandrababu ^a   Salem, Ahmed ^b  

^a BHARATHIAR UNIVERSITY   (India)

^b KING HUSSEIN CANCER CENTER   (Jordan)

Author keywords

breast cancer; LSNs; nonviral vector; p53; pCMV

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; LIPOCORTIN 5; LUMINESCENT SILICA NANOPARTICLE; MESSENGER RNA; PLASMID DNA; PROTEIN P53; SILICA NANOPARTICLE; UNCLASSIFIED DRUG; LUMINESCENT AGENT; NANOPARTICLE; SILICON DIOXIDE; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GENE THERAPY; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MCF 7 CELL LINE; MOUSE; MTT ASSAY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TOXICITY TESTING; TRYPAN BLUE ASSAY; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GENETICS; LUMINESCENCE; MCF-7 CELL LINE; MEDICINAL CHEMISTRY; PHYSIOLOGY; PLASMID; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; LUMINESCENCE; LUMINESCENT AGENTS; MCF-7 CELLS; NANOPARTICLES; PLASMIDS; SILICON DIOXIDE; TISSUE DISTRIBUTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84861451873     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01547.x     Document Type: Article

References (28)

1. Kamangar F, et al,. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150.
2. Jemal A, et al,. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
3. Li S, Huang L,. Nonviral gene therapy: promises and challenges. Gene Ther 2000; 7: 31-34.
4. Brown MD, et al,. Gene delivery with synthetic (non viral) carriers. Int J Pharm 2001; 229: 1-21.
5. Jaiswal JK, et al,. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol 2003; 21: 47-51.
6. Lingerfelt BM, et al,. Preparation of quantum dot-biotin conjugates and their use in immune chromatography assays. Anal Chem 2003; 75: 4043-4049.
7. Goldman ER, et al,. Multiplexed Toxin Analysis Using Four Colors of Quantum Dot Fluororeagents. Anal Chem 2004; 76: 684-688.
8. Santra S, et al,. Luminescent nanoparticle probes for bioimaging. J Nanosci Nanotechnol 2004; 4: 590-599.
9. Tan W, et al,. Bionanotechnology based on silica nanoparticles. Med Res Rev 2004; 24: 621-638.
10. Yao G, et al,. FloDots: luminescent nanoparticles. Anal Bioanal Chem 2006; 385: 518-524.
11. Vogelstein B, et al,. Surfing the p53 network. Nature 2000; 408: 307-310.
12. Xu L, et al,. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release 2001; 74: 115-128.
13. Kim CK, et al,. Enhanced p53 gene transfer to human ovarian cancer cellsusing the cationic nonviral vector, DDC. Gynecol Oncol 2003; 90: 265-272.
14. Lee CH, et al,. Synergistic effect of polyethylenimine and cationic liposomes in nucleic acid delivery to human cancer cells. Biochim Biophys Acta 2003; 1611: 55-62.
15. Jin Y, et al,. Toxicity of Luminescent Silica Nanoparticles to Living cells. Chem Res Toxicol 2007; 20: 1126-1133.
16. Cohen H, et al,. Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 2000; 7: 1896-1905.
17. Panyam J, et al,. Rapid endo-lysosomal escape of poly (DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002; 16: 1217-1226.
18. Prabha S, et al,. Size dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticles. Int J Pharm 2002; 244: 105-115.
19. Nowling T, et al,. Transfection of embryonal carcinoma cells at high efficiency using liposome-mediated transfection. Mol Reprod Dev 2002; 63: 309-317.
20. Uchida E, et al,. Comparison of the efficiency and safety of non-viral vector-mediated gene transfer into a wide range of human cells. Biol Pharm Bull 2002; 25: 891-897.
21. Lowe SW, et al,. p53 status and theefficacy of cancer therapy in vivo. Science 1994; 266: 807-810.
22. Rudolph C, et al,. Application of novel solid lipid nanoparticles (SLN)- gene vector formulations based on a dimeric HIV-1 TAT peptidein vitro and in vivo. Pharm Res 2004; 21: 1662-1669.
23. Coll JL, et al,. Anti tumor activity of bax and p53 naked gene transfer in lung cancer: in vitro and in vivo analysis. Hum Gene Ther 1998; 9: 2063-2074.
24. Nchinda G, et al,. Characterization of cationic lipid DNA transfection complexes differing in susceptability to serum inhibition. BMC Biotechnol 2002; 2: 12-21.
25. Klejbor I, et al,. ORMOSIL nanoparticles as a non-viral gene delivery vector for modeling polyglutamine induced brain pathology. J Neurosci Methods 2007; 165: 230-243.
26. Kneuer C, et al,. Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA. Int J Pharm 2000; 196: 257-261.
27. Sha J, Kaiming Y,. Nanoparticle-mediated drug delivery and gene therapy. Biotechnol Prog 2007; 23: 32-41.
28. Xian X, et al,. Novel amino-modified silica nanoparticles as efficient vector for hepatocellulaar carcinoma gene therapy. Med Oncol 2010; 27: 1200-1207.